Navigation Links
Circulating tumor cells in blood can predict a patient's response to chemotherapy
Date:12/3/2013

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer. The key lies in identifying specific proteins in these cells, which make them particularly sensitive to specific drugs.

The scientists, from the Circulating Tumour Cells and Metastasis research group of GENYO (Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Govt.) have received an award at the 9th International Symposium on Minimal Residual Cancer, held recently in Paris, for their study into the use of CTCs and specific markers in these cells, as a clinical tool to determine the response to treatments administered to patients with advanced cancer of the colon.

The patients, studied in the Oncology Unit of the Clinical Hospital of Granada and the Hospital of Motril, underwent a standard treatment in this illness, which includes chemotherapy and a specific monoclonal antibody that reduces the vascularization of the tumour. The study was carried out in collaboration with the Roche Farma laboratory.

The importance of CTCs as the origin of metastasis, which, in turn, is the cause of more than 9 out of every 10 deaths from cancer, has been the subject of work by this group in GENYO for over four years, lead by the University of Granada professors, Jos Antonio Lorente, Mara Jos Serrano and Jos Luis Garca Puche.

GENYO co-operates actively with other Spanish hospitals such as Jan (Dr. Snchez Rovira's team), Crdoba (Dr. Aranda's team) or Almera - Torrecrdenas (with Dr. Juan Torres), as well as carrying out other particularly relevant collaborations with the Dexeus Institute or the Hospital del Mar in Barcelona, along with others in Granada (teams led by Drs. Expsito, Delgado, Czar and Cueto, among others).

Eight Studies

This test on CTCs is one of eight studies the Granada research group is currently carrying out on patients affected by various particularly relevant pathologies in oncology, such as breast cancer, lung cancer, peritoneal carcinomatosis or prostate cancer. These studies have been funded by the Andalusian Regional Government's Health Council, the University of Granada and the pharmaceutical sector.

Due to the importance of this research in applying anti-cancer treatments with greater precision and with fewer side-effects, as well as the importance of CTCs in diagnosing the illness, the work of this GENYO group has caught the attention of the pharmaceutical industry, which habitually collaborates in the carrying out of some of the studies, such as SANOFI, Pangaea, Janssen, Amgen, Ingeniatrix or Roche Farma.


'/>"/>

Contact: José Antonio Lorente
jlorente@ugr.es
34-958-715-500
University of Granada
Source:Eurekalert  

Related medicine news :

1. New research finds flu shot effective regardless of circulating flu strain
2. Sous Vide Circulating Bath Systems Enable Chefs to Achieve Perfect Results
3. Detecting circulating tumor cells
4. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
5. Capturing circulating cancer cells could provide insights into how disease spreads
6. Blocking antioxidants in cancer cells reduces tumor growth in mice
7. Why tumors become resistant to chemotherapy?
8. New immunotherapy for malignant brain tumors
9. Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
10. American Brain Tumor Association-Funded Research Spurs Development of New Treatments
11. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Circulating tumor cells in blood can predict a patient's response to chemotherapy
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has ... Diego, CA, on February 6th & 7th, 2016 according to kicking coach Michael Husted. ... not invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. ... Nestlé KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , ... quality of their product, through activities that focus on better farming, better lives and ...
(Date:2/10/2016)... Fort Walton Beach, Florida (PRWEB) , ... February ... ... that the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at ... new platform, MetLoop has “put the power of the world's most advanced weather ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Guard, to associations of medical professionals throughout the country. The Guard was specifically ... assessments, policies and procedures, employee training, regulatory updates, and compliance coaching. , In ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... England och PITTSBURGH ... Erbjudandet lämnas inte, och detta pressmeddelande ... indirekt, i eller till, och inga anmälningssedlar ... av aktieägare i, något land där Erbjudandet, ... accept av Erbjudandet skulle strida mot tillämpliga ...
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the market ... treatment of Benign Prostatic Hyperplasia (BPH), announces new private ... Keswani , a medical device industry veteran of more ... Limited Liability Company.  Plymouth, Minn. ... lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue ...
Breaking Medicine Technology: